Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
← catalyst calendarNCT03992417 · readout in 224 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
955actual
Sites
105
Countries
Argentina, Australia, Austria +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-11 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-06-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Intervention
- Drug: Dupilumab SAR231893 (REGN668) — also filed as Dupixent®
Primary outcomes
what the primary-completion date above is the date OFBaseline Characteristics: Medical history
measured Baseline to Month 60
Baseline Characteristics: Socio-demographics
measured Baseline to Month 60
Baseline Characteristics: Disease characteristics
measured Baseline to Month 60
Publications
- PMID 39621227 — linked by the registry
- PMID 37801232 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed